Unigen, Inc.

36 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Dec 2 to 9, 2026 · next Dec 2
2 fees due Feb 4 to 28, 2027 · next Feb 4
1 fee due Apr 8, 2027
The maintenance fee for Bakuchiol Compositions for Treatment of Post Inflammatory Hyperpigmentation (US 10,434,073) comes due Apr 8, 2027. Unpaid by Oct 8, 2027, it lapses early.
1 fee due May 7, 2027
The maintenance fee for Compositions, methods, and medical compositions for treatment of and maintaining the health of the liver (US 11,806,379) comes due May 7, 2027. Unpaid by Nov 8, 2027, it lapses early.
3 fees due Sep 5 to 30, 2027 · next Sep 5

Which patents, and when each one lapses · Pro

Recent changes

2 terms have ended since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 8,771,761	Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria In force Ends no later than Oct 12, 2027 · From the USPTO record	In force	Ends no later than Oct 12, 2027	From the USPTO record
US 9,623,068	Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria In force Term ends Feb 27, 2028 · From the USPTO record	In force	Term ends Feb 27, 2028	From the USPTO record
US 8,247,007	Composition for treating atopic dermatitis comprising extracts of bamboo and Scutellaria In force Term ends Nov 7, 2028 · From the USPTO record	In force	Term ends Nov 7, 2028	From the USPTO record
US 8,852,657	Chromones as therapeutic agents In force Term ends Feb 6, 2029 · From the USPTO record	In force	Term ends Feb 6, 2029	From the USPTO record
US 10,905,654	Compositions of bakuchiol and methods of making the same In force Term ends May 15, 2029 · From the USPTO record	In force	Term ends May 15, 2029	From the USPTO record
US 8,362,305	Series of Skin Whitening (LIGHTENING) Compounds In force Term ends Jul 21, 2029 · High confidence	In force	Term ends Jul 21, 2029	High confidence
US 8,658,838	Series of Skin Whitening (LIGHTENING) Compounds In force Term ends Jul 21, 2029 · High confidence	In force	Term ends Jul 21, 2029	High confidence
US 9,096,507	Series of Skin Whitening (LIGHTENING) Compounds In force Term ends Jul 21, 2029 · High confidence	In force	Term ends Jul 21, 2029	High confidence
US 9,682,910	Series of Skin-Whitening (LIGHTENING) Compounds In force Term ends Jul 21, 2029 · High confidence	In force	Term ends Jul 21, 2029	High confidence
US 10,259,764	Series of Skin Whitening (Lightening) Compounds In force Term ends Jul 21, 2029 · Medium confidence	In force	Term ends Jul 21, 2029	Medium confidence

10 of 36 patents shown.

Pro members see all 36.

Pro members: see all 36 patents

Also on record, not counted in the 36: 17 lapsed for an unpaid fee · 40 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

9 pending · 4 abandoned · 19 no status recorded

List them